Latest Sprint Bioscience News & Updates

See the latest news and media coverage for Sprint Bioscience. We track all announcements, press releases, and industry mentions in real time, all in one place.

Sprint Bioscience

Pharmaceutical company developing oncology drug candidates

sprintbioscience.com

Founded year: 2009
Company type: Public company
Number of employees: 48–50
Industry: Pharmaceuticals

Last updated August 26

Latest news about Sprint Bioscience

In short: Sprint Bioscience sold TREX1 to Gilead for up to $400M and reported positive pipeline data.

Company announcements

August 26 Sprint Bioscience

Sprint Bioscience publishes interim report for January to June 2026

Financial key figures are reported simultaneously with new strategic partnerships and ongoing drug development presented.

May 19 Sprint Bioscience

Sprint Bioscience published Q1 2026 interim report

The quarter saw high activity and progress across development programs; Redeye issued a research update.

May 13 Sprint Bioscience

Sprint Bioscience releases Q1 report with key figures and program data

The company reports positive preclinical results for VRK1, DCPS and NNMT. Jenni Björnulfson is appointed CFO.

February 11 Sprint Bioscience

Sprint Bioscience sold the TREX1 program for up to USD 400 million

The company reported a profit for the full year 205 and strengthened its cash position. The VRK1 program is being taken back after partner termination.

Media coverage

August 26 BioStock

Increased interest and new AI agreement for Sprint Bioscience - CEO comments on Q2 - Biostock

Huddinge-based Sprint Bioscience develops preclinical small-molecule drug programs with first-in-class potential, which are then licensed to international pharmaceutical companies. The company is currently marketing five programs: VRK1, VPS34, NNMT...

November 25, 2025 PharmiWeb

Gilead acquires Sprint's pre-clinical TREX1 cancer programme

Gilead Sciences has struck a deal with Sprint Bioscience to license a pre-clinical oncology programme targeting TREX1. Under the agreement, Gilead will pay an initial...

November 20, 2025 Yahoo Finance

Gilead snaps up Sprint’s TREX1 immunotherapy programme for $400m

Gilead Sciences has secured the rights to Sprint Bioscience’s preclinical oncology programme for up ...

February 12, 2018 Dagens industri

Sprint Bioscience

Research company Sprint Biosciences announced on Monday morning that the cancer program Trex1 has been sold to American Gilead Sciences. The stock surges 135 percent in the initial trading on First...

Never miss news about Sprint Bioscience

Track Sprint Bioscience and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Sprint Bioscience competitors & trending companies

Browse news for competitors to Sprint Bioscience and other trending companies.